In human cells, telomerase activity is tightly regulated by the expression of its catalytic subunit, namely, the human telomerase reverse transcriptase (hTERT). However, the molecular mechanisms involved in the regulation of hTERT expression have not been completely clarified. We have previously reported that transforming growth factor b (TGF-b) represses the expression of the hTERT gene. In the present study, we demonstrated that TGF-bactivated kinase 1 (TAK1), originally identified as a mitogen-activated kinase kinase kinase, represses the hTERT core promoter activity in an E-box-independent manner, and it also represses the transcription of the hTERT gene in human lung adenocarcinoma cell line, A549 cells. This TAK1-induced repression was found to be caused by the recruitment of histone deacetylase to Sp1 at the hTERT promoter and a consequent reduction in the amount of acetylated histone H4 at the hTERT promoter. Finally, we demonstrated that TAK1 induces cellular senescence programs in normal human diploid cells. Thus, we assume that TAK1 triggers the repression mechanisms of the hTERT gene as a result of evoking cellular senescence programs. Considered together, TAK1 is thought to play a causative role in the determination of a finite replicative lifespan of normal and cancer cells.
Introduction
In cancer cells, telomerase -a complex ribonucleoprotein enzyme -synthesizes telomeric repeats to avoid telomere loss that accompanies cell division and chromosomal replication. Researchers have been investigating the regulatory mechanisms of telomerase that determine the immortality of cancer cells. Although the increasing evidences obtained to date have indicated that telomerase regulation is complex (Aisner et al., 2002; Katakura et al., 2005) , significant research efforts have been focused on the transcriptional regulation of the human telomerase reverse transcriptase (hTERT) gene (Kyo and Inoue, 2002) .
The expression of hTERT is governed by complex regulatory pathways. The oncoprotein c-Myc was reported to activate the hTERT core promoter by binding to the E-boxes located at the promoter site (Cong et al., 1999; Horikawa et al., 1999) . Further, the identified cis-elements also include the Sp1-binding sites (GC-boxes) at the core promoter that are crucial for the transactivation of the hTERT gene (Horikawa et al., 1999; Takakura et al., 1999) . A number of factors that directly or indirectly affect the hTERT promoter activity have been identified. Recently, several researchers have proposed mechanisms of transcriptional silencing of the hTERT gene in normal cells. Experiments on a wide variety of normal human somatic cells with trichostatin A (TSA), an inhibitor of histone deacetylase (HDAC), suggest that histone deacetylation is essential to the transcriptional silencing of the hTERT gene (Cong and Bacchetti, 2000; Takakura et al., 2001; Xu et al., 2001) and that Sp1 and Sp3 associate with the hTERT promoter, recruiting HDAC for localized histone deacetylation (Hou et al., 2002; Won et al., 2002) .
We have previously demonstrated that transforming growth factor b (TGF-b) can repress hTERT gene expression, leading to telomere shortening in the human lung adenocarcinoma cell line, that is, A549 cells (Katakura et al., 1999) . In the process of identifying the signal transduction pathway that represses the hTERT gene, we found that TGF-b-activated kinase 1 (TAK1), originally identified as a mitogen-activated kinase kinase kinase (MAPKKK) that functions in the TGF-b signaling pathway (Yamaguchi et al., 1995) , triggers signals to repress the hTERT promoter. In the present study, we performed systematic analyses of the hTERT promoter to identify such repressive DNA elements and interacting regulatory factors; we then demonstrated that the TAK1 signal represses the hTERT transcription by inducing HDAC recruitment to Sp1 on the hTERT promoter. We suggest that TAK1 signals evoke the HDAC-dependent repression mechanism of hTERT transcription that occurs in normal human somatic cells.
Results

TAK1 represses hTERT gene transcription
To clarify the signal transduction pathway involved in hTERT gene regulation, we performed a transient expression assay using A549 cells and luciferase reporter plasmids containing a 1.3-kb region upstream from the initiating ATG codon (À1391 to À25) and 5 0 -truncations. The cell lysates from A549 cells transfected with the reporter plasmid and effector plasmids were used for the luciferase assay. In the present study, we tested for the involvement of TAK1, a member of the MAPKKK family, in the regulation of hTERT promoter activity. Co-transfection of TAK1 and TAK1-binding protein 1 (TAB1), which is known to activate the TAK1 signaling pathway, markedly repressed the hTERT promoter activity (Figure 1a ). This hTERT promoter repression by TAK1/TAB1 is observed in all 5 0 -truncated reporters, suggesting that the regulatory cis-elements involved 0 -truncated fragments of the hTERT promoter fused with the luciferase reporter plasmid pGL3-Basic were used as reporter plasmids, and luciferase assays were performed using the Dual-Luciferase Reporter Assay System. A549 cells were cotransfected with the reporter plasmid along with expression plasmids for either TAK1 and TAB1 (TAK1/TAB1) or with the control plasmid pcDNA3. Three days after the transfection, the cells were harvested and assayed for luciferase activity. (b) Nucleotide sequence of the hTERT proximal promoter. À1 indicates the first 5 0 -nucleotide from the translation initiation site. E-box and GC-box are indicated as boxes. The initiation codon ATG is underlined. (c) Co-introduction of TAK1 and TAB1 is required for the repression of the hTERT core promoter. The hTERT core promoter, fused to the luciferase reporter plasmid pGL3-Basic (phTERTp-289), was used as the reporter plasmid. A549 cells were co-transfected with the phTERTp-289 along with the indicated combinations of expression plasmids for TAK1, TAB1, and the dominant negative mutant of TAK1, namely K63W, and luciferase assays were performed as described above. In these experiments, the total DNA amount for each transfection was kept constant (510 ng) by using an empty plasmid. The data shown here is representative of the three separate experiments. (d-e) Activation of endogenous TAK1 results in the repression of hTERT gene transcription in A549 cells. The cells were transfected with 5 nM siRNA directed against TAK1 by using the HiPerFect transfection reagent and cultured for 5 days. Cells were then transduced with recombinant adenoviruses for TAK1 and TAB1 or with control adenovirus (null) and cultured for a further 3 days. The TAK1 and hTERT expression levels in these cells were assessed by quantitative real-time PCR in triplicate and normalized to the corresponding GAPDH.
TAK1 represses hTERT transcription T Fujiki et al in this repression are located in the first 164 bp of the hTERT promoter, which has been identified as the core promoter region essential for the transcriptional activation of the hTERT gene and contains several potential transcription factor-binding elements such as the GCbox and E-box (Figure 1b) (Cong et al., 1999; Horikawa et al., 1999; Takakura et al., 1999; Won et al., 2002) .
Next, we confirmed the involvement of the TAK1 signaling pathway in the hTERT promoter repression by using a kinase-deficient mutant of TAK1, namely K63W (Shibuya et al., 1996) , in the luciferase assay. We used phTERTp-289 as a reporter plasmid for investigating the TAK1-mediated hTERT promoter repression because the promoter fragment (À289 to À25) contains two E-box elements that were reported to be important for hTERT promoter regulation (Cong et al., 1999; Horikawa et al., 1999; Takakura et al., 1999) . Figure 1c shows that the co-transfection with TAK1/TAB1 greatly repressed the hTERT promoter activity, whereas the transient transfection with TAK1, TAB1, or K63W and TAB1 attenuated the suppressive effects on the hTERT promoter. These results demonstrate that TAK1 transmits signals to repress the hTERT promoter and that TAK1 activation by TAB1 is indispensable for this repression.
Further, we investigated the involvement of endogenous TAK1 in the hTERT repression. After A549 cells were transfected with siRNA directed against TAK1, they were transduced with TAK1 and TAB1 by using recombinant adenoviruses (Figure 1d and e). TAK1, hTERT and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expressions were assessed by quantitative real-time PCR analysis. As shown in Figure 1e , a marked reduction in the hTERT expression was observed in the A549 cells transduced with TAB1 as well as both TAK1 and TAB1, whereas this repression was attenuated by reducing TAK1 expression by using siRNA against TAK1. These results indicate that the activation of endogenous TAK1 results in the repression of hTERT transcription in cancer cells.
TAK1 represses hTERT gene transcription in an E-box-independent manner First, we examined the E-box dependency of TAK1-induced repression of the hTERT promoter by using phTERTp-289EM, in which two E-box elements were disrupted by site-directed mutagenesis. As shown in Figure 2a , TAK1 and TAB1 markedly repressed the activity of phTERTp-289EM as well as wild-type hTERTp-289, indicating that TAK1 repressed the hTERT promoter in an E-box-independent manner and by using cis-elements other than E-boxes.
Next, we investigated a possible crosstalk between c-Myc and TAK1 signals to regulate the hTERT promoter activity. As shown in Figure 2b , c-Myc activated the hTERT promoter activity in an E-boxdependent manner. However, the TAK1-induced repression of the hTERT promoter was observed in the wild-type and mutant hTERT promoters. These results indicate that c-Myc and TAK1 may act independently to regulate the hTERT promoter activity by using different cis-elements. When TAK1/TAB1 were coexpressed along with c-Myc, the wild-type hTERT promoter displayed moderate activity, suggesting that the effects of TAK1/TAB1 and c-Myc on the hTERT promoter activity nullify each other. Simultaneously, the promoter activity of phTERTp-289EM was markedly repressed, similar to that in the absence of c-Myc. These results demonstrate that c-Myc and TAK1 signals crosstalk with each other on the hTERT core promoter to tightly regulate the hTERT promoter activity by using different cis-elements.
The effect of TAK1 on the DNA-binding abilities of the Sp1 family proteins When considered together with the fact that the major cis-elements located in the hTERT core promoter comprise two E-boxes and five GC-boxes, we anticipated that Sp1 might be involved in the E-box-independent repression of the hTERT promoter triggered by TAK1. To test this hypothesis, we investigated any change that occurred in the DNA-binding ability of Sp1 after the activation of the TAK1 pathway. An electrophoretic mobility shift assay (EMSA) was performed using nuclear extracts from the A549 cells transduced with TAK1/TAB1 or LacZ and a 32 P-labeled consensus Sp1 oligonucleotide. We found that three DNA-protein complexes (*, ** in Figure 3a ) specifically competed with the unlabeled competitor, and the slowest (*) and the other two mobility bands (**) were supershifted by . Figure 3b shows that no additional bands appeared after transduction with TAK1/TAB1. Furthermore, no significant alteration in the band shift patterns could be detected. These results suggest that the TAK1-induced repression of the hTERT promoter is not caused by decrease in the DNA-binding ability of the Sp1 family proteins.
Involvement of HDAC in the TAK1-induced repression of the hTERT promoter Next, we investigated any change that occurred in the transcriptional activation ability of Sp1 after transduction with TAK1/TAB1. Here, we took advantage of a GAL4-Sp1 system in which the N-terminal domain of Sp1 was fused with the GAL4 DNA-binding domain (Emami et al., 1995) . This GAL4 fusion construct was co-transfected with pFR-Luc, a luciferase reporter plasmid containing five consensus GAL4-binding sites along with TAK1 and TAB1 expression plasmids in A549 cells, and the cell lysates were used to perform the luciferase assay. The results indicate that the transcriptional activation by Sp1 (amino acids 83-778) was significantly repressed by TAK1 in a dose-dependent manner ( Figure 4a ). These results suggest that the TAK1-induced repression of the hTERT promoter can be attributed to the attenuated transcriptional activation ability of Sp1. 
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We assumed that Sp1 recruits a transcriptional repressor in response to a TAK1 signal. Several researchers have suggested that Sp1-mediated transcriptional activation of the hTERT promoter is blocked by HDAC recruitment in normal human somatic cells (Won et al., 2002) . Thus, we investigated HDAC involvement in the TAK1-induced attenuation of Sp1 transcriptional activation by using the HDAC inhibitor TSA. As shown in Figure 4b , TSA significantly relieved the TAK1-induced attenuation of Sp1 transcriptional activation, demonstrating HDAC involvement. Further, TSA relieved the TAK1-induced repression of the wildtype and mutant hTERT promoter activities (Figure 4c ), demonstrating that HDAC is also involved in the TAK1-induced hTERT promoter repression. These results suggest that TAK1 induces HDAC recruitment to Sp1 on the hTERT promoter, resulting in transcriptional silencing of the hTERT gene.
Subsequently, we examined the interaction of Sp1 and HDAC with the hTERT promoter by a chromatin immunoprecipitation (ChIP) assay. As shown in Figure 5a , Sp1 interacted with the hTERT promoter, whereas the amount of Sp1 bound to the hTERT promoter decreased upon the TAK1 signal. Further, TAK1 induced HDAC2 recruitment to the hTERT promoter ( Figure 5b ). Next, we examined the physical interaction between Sp1 and HDAC2 by co-immunoprecipitation. After the A549 cells were transfected with pcDNA-Sp1-N-HA, which expresses the N-terminal domain of Sp1 (1-623) with HA, we immunoprecipitated the Sp1-N protein complexes with anti-HA antibodies, and the complexed HDAC2 was detected using an anti-HDAC2 antibody. The result shows that Sp1 forms complexes with HDAC2 in the presence of the TAK1 signal ( Figure 5c ) and suggests that TAK1 induces HDAC2 recruitment to Sp1 at the hTERT promoter.
In addition, these results led us to assume that histone acetylation at the hTERT promoter is altered by the TAK1 signal. Therefore, we attempted to detect any changes in histone acetylation at the hTERT promoter on receiving the TAK1 signal. Using the ChIP assay, we examined the abundance of acetylated histone associated with the hTERT promoter (Figure 5d ). An abundant acetylated H4 histone level was found to be present at the hTERT promoter in the A549 cells. TSA treatment had little effect on the further accumulation of acetylated H4 histone. A significant reduction was noted in the acetylated H4 histone amount on transduction with TAK1/TAB1, and following the TSA treatment, a substantial acetylated H4 histone amount was recovered. Similar lines of results were obtained in histone H3 acetylation (data not shown). These changes in the amounts of acetylated H4 histone correlated with a decreased hTERT expression by transduction with TAK1/TAB1 and its recovery on TSA treatment (Figure 5e ). Further, this reduction in the amount of acetylated H4 histone following the TAK1 signal was partially recovered by c-Myc (Figure 5f ). This result suggests that TAK1 and c-Myc antagonize each other in regard to the acetylation status of H4 histone.
All these results suggest that the TAK1 signal induces HDAC2 recruitment to Sp1 at the hTERT promoter, resulting in the reduction in acetylated H4 histone at the hTERT promoter and consequently in the transcriptional silencing of the hTERT gene. induces physical interaction between Sp1 and HDAC2. A549 cells were transfected with expression plasmids for TAK1 and TAB1 along with pcDNA3-Sp1-N-HA. Three days after the transfection, the whole-cell lysates were immunoprecipitated with anti-HA antibody and an irrelevant control mouse IgG. The immunocomplexes were separated by SDS-PAGE and immunoblotted with anti-HDAC2 antibody or anti-HA antibody. (d) TAK1-induced histone H4 deacetylation at the hTERT promoter region. A549 cells were transduced with TAK1/TAB1 or with null and cultured for 2 days. Where indicated, the cells were treated with 1 mM TSA for 24 h. The ChIP assay was performed to identify the acetylation status of histone H4 at the hTERT promoter region. (e) TSA relieved the TAK1-induced repression of hTERT transcription in the A549 cells. A549 cells were transduced with TAK1/TAB1 or LacZ by recombinant adenoviruses, cultured for 2 days, and then treated with 100 nM TSA for 24 h. Total RNA preparation and the subsequent RT-PCR procedures have been described previously. (f) TAK1 and c-Myc antagonize each other regarding histone H4 acetylation. A549 cells were transduced with TAK1/TAB1 or with null and cultured for 2 days. The cells were further transfected with the c-Myc expression plasmid or mock. The acetylation status of histone H4 at the hTERT promoter was assessed as described above.
The role of TAK1 in normal human diploid cells Finally, we investigated the role of TAK1 in the repression of hTERT transcription in normal human diploid cells, TIG-1 cells. As shown in Figure 6a , the repression of hTERT transcription in TIG-1 cells was partially relieved by reducing TAK1 expression by using siRNA. This result suggests that TAK1 also participates in the repression of hTERT transcription in normal human diploid cells. Next, we investigated the consequences of the ectopic TAK1 expression in TIG-1 cells. Results show that ectopically expressed TAK1 induced growth inhibition, morphological change, and senescence-associated bgalactosidase activity in TIG-1 cells (Figure 6b-f) , demonstrating that TAK1 induces a cellular senescence program in normal human diploid cells.
Discussion
Several studies have been conducted to clarify the regulatory mechanisms of the hTERT promoter. The E-box elements located in the core promoter region and the transcription factors that bind to it have been specifically focused upon. Several reports have demonstrated the critical role of c-Myc and its network proteins in regulating the hTERT promoter (Xu et al., 2001; Ducrest et al., 2002) and suggested that the ability of c-Myc to activate hTERT expression is one mechanism by which c-Myc exhibits its critical role. A large number of studies have reported the activation mechanisms of the hTERT promoter, whereas only a few studies have reported the repression mechanisms of the hTERT promoter (Ducrest et al., 2002) . We have previously reported that TGF-b can repress telomerase activity and hTERT transcription in the A549 cells (Katakura et al., 1999) . In the course of our study, which aimed to clarify the molecular mechanisms underlying the hTERT repression, we found that TAK1, originally identified as an MAPKKK functioning in the TGF-b signaling pathway (Yamaguchi et al., 1995) , signals to repress the hTERT transcription. In the present study, we demonstrated the molecular mechanisms for TAK1-induced hTERT repression.
Several researchers have described the repression mechanisms of the hTERT promoter, focusing on the E-boxes located in the core promoter region of the hTERT gene and the transcription factors bound to them. Such transcription factors, for example Mad1 and MT-box-binding factor, have been reported to function as repressors of the hTERT promoter that act when cancer cell differentiation is induced by antagonizing the transcriptional activation ability of c-Myc (Tzukerman et al., 2000; Xu et al., 2001; Horikawa et al., 2002) . Although our results showed that TAK1 represses the hTERT promoter activity in an E-box-independent manner, we cannot exclude the possibility that TAK1 represses the hTERT promoter even in an E-box-dependent manner. In fact, a b-catenin/Tcf-4 complex augments c-Myc gene transcription by binding to the Tcf-4-binding sites in the c-Myc promoter (He et al., 1998) ; however, this binding is impaired by the MAPK-related NEMO-like kinase (NLK) pathway activated by TAK1 (Ishitani et al., 1999) . Thus, in the future, we must investigate whether TAK1 represses c-Myc expression by activating the NLK pathway and consequently antagonizing the b-catenin/Tcf-4 complex and whether this c-Myc repression results in hTERT promoter repression in an E-box-dependent manner.
In the present study, we focused upon the E-boxindependent repression mechanisms of the hTERT promoter by the TAK1 signal. Our results demonstrated that TAK1 represses the hTERT promoter in an E-boxindependent manner through the cis-elements located in the core promoter region, suggesting that Sp1 plays a key role in this repression. However, the TAK1 signal did not have a significant effect on the DNA-binding abilities of the Sp1 family proteins as evidenced by 
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EMSA. We thus investigated any change that occurred in the transcriptional activation ability of Sp1 by the TAK1 signal. Several proteins were reported to repress the hTERT promoter activity by binding to Sp1 (Ducrest et al., 2002) . Further, the Sp1 family proteins associate with the hTERT promoter, recruiting HDAC for histone deacetylation and transcriptional silencing of the hTERT gene in normal human somatic cells (Cong and Bacchetti, 2000; Takakura et al., 2001; Xu et al., 2001; Hou et al., 2002; Won et al., 2002) . We then investigated the possible involvement of the Sp1 family proteins and HDAC in the TAK1-induced hTERT gene repression. Results clearly demonstrate that the TAK1 signal regulates the localized deacetylation of the histones on the hTERT promoter and the transcriptional silencing of the hTERT gene through inducing HDAC2 recruitment to the hTERT promoter and the physical interaction between Sp1 and HDAC2 and by counteracting with c-Myc. Further, the TAK1-induced decrease in the amount of Sp1 bound to the hTERT promoter might reflect the changes in the amount and composition of regulatory factors bound to the hTERT promoter.
This study has indicated that the transcriptional adaptor molecules bound to Sp1 play a key role in the regulation of the hTERT promoter in cancer cells and demonstrated for the first time that TAK1 signals activate the Sp1-dependent repression mechanisms of the hTERT promoter that functions in the normal human somatic cells. In the present study, we further demonstrated that TAK1 triggers cellular senescence programs in normal human diploid cells. Therefore, we assume that TAK1 represses hTERT gene transcription in cancer cells as a result of evoking cellular senescence programs. Thus, TAK1 is thought to play a causative role in the determination of a finite replicative lifespan of normal and cancer cells. These results suggest that TAK1 and its downstream mediators are expected to be novel targets for developing anticancer drugs.
Materials and methods
Cell culture and reagents A549 cells were cultured in eRDF medium (Invitrogen, Carlsbad, CA, USA), supplemented with 5% fetal bovine serum (FBS; Invitrogen); and HEK293 cells (JCRB9068; HSRRB, Osaka, Japan), in Dulbecco's modified Eagle's medium (DMEM; Invitrogen) supplemented with 10% FBS at 371C in 5% CO 2 . TIG-1 cells (Institute of Development, Aging and Cancer, Tohoku University, Miyagi, Japan) were cultured in MEM medium (Nissui, Tokyo, Japan) supplemented with 10% FBS at 371C in 5% CO 2 . TSA, an inhibitor of HDAC, was purchased from Sigma (St Louis, MO, USA). TSA was dissolved in Me 2 SO and added to the culture medium at a final concentration of 100-1000 nM. A corresponding volume of Me 2 SO was added to the control cells.
hTERT promoter-reporter constructs A human genomic library in lDASH II (Stratagene, La Jolla, CA, USA) was screened with a 32 P-labeled probe consisting of the 5 0 region (À50 to þ 852 relative to the translation initiation site ( þ 1) of the hTERT cDNA that was kindly provided by R Weinberg (Massachusetts Institute of Technology, Cambridge, MA, USA); subsequently, we obtained clones containing the 5 0 -flanking region of the hTERT gene. The nucleotide sequences of these clones were identical to those deposited in GenBank (AF098956 and AF097365). Various lengths of the DNA fragments located upstream of the initiation codon ATG were amplified using PCR and inserted into the firefly luciferase reporter plasmid pGL3-Basic (Promega, Madison, WI, USA). Two E-box elements in the isolated hTERT promoter region (À242 to À237 and À34 to À29) were changed from CACGTG to TTTGTG by using the GeneEditor in vitro Site-Directed Mutagenesis System (Promega).
Transfection and luciferase assay A549 cells were seeded at a concentration of 1 Â 10 5 cells per well and cultured overnight. Luciferase reporter and effector plasmids were co-transfected along with the Renilla luciferase plasmid pRL-TK (Promega) to standardize the efficiency of transcription into the A549 cells by using LipofectAMINE PLUS reagent (Invitrogen) according to the manufacturer's instructions. The cells were exposed to the transfection mix for 3 h and harvested for analysis after 72 h. The transfected cells were cultured in the presence of 100-300 nM TSA for 72 h to study the effect of TSA on the promoter activity. Luciferase assays were performed using the Dual-Luciferase Reporter Assay System (Promega). The relative luciferase activity was calculated by dividing the firefly luciferase activity by the Renilla luciferase activity. These experiments were repeated at least three times. The standard deviations are shown in the figures.
To evaluate the transcriptional activation activity of Sp1, we used a GAL4-Sp1 plasmid gifted by S Smale (UCLA, Los Angeles, CA, USA) (Emami et al., 1995) , which contains most of the human Sp1 cDNA (amino acids 83-778) fused to the DNA-binding domain of the yeast transcription factor GAL4 (amino acids 1-147) and pFR-Luc (Stratagene), a luciferase reporter vector containing five GAL4-binding sites. The transfection and luciferase assays were performed as mentioned above.
Recombinant adenovirus and transductions
We produced recombinant adenovirus by using the Adeno-X Expression System (BD Biosciences Clontech, Palo Alto, CA, USA) according to the manufacturer's protocol. Recombinant adenoviruses were prepared by disrupting HEK293 cells transfected with recombinant adenoviral DNA including TAK1, TAB1 or LacZ cDNA. The A549 cells underwent adenoviral transduction for 3 days after a 1-h infection at a multiplicity of infection (moi) of 20-50.
Electrophoretic mobility shift assay Nuclear extracts were prepared from the subconfluent cultures of A549 cells transduced with recombinant adenoviruses expressing TAK1/TAB1 or LacZ by using the NE-PER Nuclear and Cytoplasmic Extraction Reagent kit (Pierce, Rockford, IL, USA) according to the manufacturer's instruction. A double-stranded oligonucleotide primer (5 0 -ATTC GATCGGGGCGGGGCGAGC-3 0 ) containing a consensus binding site for Sp1 was end-labeled with [g-32 P]ATP (Amersham Biosciences, Piscataway, NJ, USA) by using T4 polynucleotide kinase (Promega) and was used as a probe. An equal amount of a radioactive probe was added for the binding reactions containing 5 mg nuclear extract protein in 10 ml buffer containing 10 mM Tris-HCl (pH 7.5), 10 mM TAK1 represses hTERT transcription T Fujiki et al MgCl 2 , 100 mM NaCl, 0.5 mM EDTA, 0.5 mM DTT, 4% glycerol, and 0.1 mg ml À1 poly(dI-dC). The reaction mixtures were incubated for 25 min at 251C before separation on nondenaturing 4% polyacrylamide gels at 41C and were visualized using BAS 1000 image analyzer (Fuji film, Tokyo, Japan). Two micrograms of anti-Sp1 (sc-420; Santa Cruz Biotech, Santa Cruz, CA, USA) or anti-Sp3 (sc-644; Santa Cruz Biotech) was added to the binding reaction before adding the probe, and the mixtures were incubated for an additional 60 min at 41C. An unlabeled oligonucleotide, acting as a competitor, was added immediately before the addition of the probe at 50-fold molar excess.
Chromatin immunoprecipitation assay
ChIP assay was performed using the ChIP assay kit (Upstate, Charlottesville, VA, USA) according to the manufacturer's protocol. In brief, A549 cells were transduced with recombinant adenovirus and cultured for 2 days. Transduced cells were either maintained as control or treated with 1 mM TSA for a further 16 h. The cells were then crosslinked using 1% formaldehyde for 10 min at room temperature. After washing with PBS, the cell pellet was resuspended in SDS lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl (pH 8.1), 1 mM phenylmethylsulfonyl fluoride (PMSF), 1 mg ml À1 aprotinin, and 1 mg ml À1 pepstatin A) and incubated on ice for 10 min. Next, 100 ml of the supernatant of the sonicated chromatin solution was diluted with 900 ml of ChIP dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl (pH 8.1), 167 mM NaCl, 1 mM PMSF, 1 mg ml À1 aprotinin, and 1 mg ml À1 pepstatin A) and precleared by incubating with 80 ml salmon sperm DNA/protein A agarose-50% slurry for 30 min at 41C. The supernatant was incubated overnight at 41C either with anti-Sp1 antibody (1C6; Santa Cruz Biotech), anti-HDAC2 antibody (H-54; Santa Cruz Biotech), or anti-acetyl-Histone H4 antibody (06-866; Upstate). The immunocomplexes thus formed were collected using 60 ml of salmon sperm DNA/protein A agarose-50% slurry and eluted two times with 250 ml elution buffer (1% SDS and 0.1 M NaHCO 3 ) after extensive washings, and the crosslinkage was reversed by heating at 651C for 6 h, followed by treatment with 80 mg ml À1 proteinase K at 451C for 60 min. The DNA was recovered by ethanol precipitation and used as a template for PCR to amplify the target site in the hTERT promoter. The target site and the corresponding primer sequences are as follows: 5 0 -GGCCGGGCTCCCAGTGGA TTCG-3 0 (À293 to À272) and 5 0 -CAGCGGGGAGCGCGCG GCATCG-3 0 ( þ 20 to À2). The PCR products were subjected to electrophoresis in 2% agarose gel.
Co-immunoprecipitation
Co-immunoprecipitation was performed with minor modifications that were described previously (Won et al., 2002) . Wholecell extracts were prepared from transfected A549 cells in a lysis buffer containing 150 mM NaCl, 50 mM Tris (pH 8.0), 1% NP-40, and complete protease inhibitor cocktail (Roche, Indianapolis, IN, USA). After centrifuging the lysate at 16 000 Â g for 15 min at 41C, anti-HA antibody (12CA5; Roche) was added to the supernatant and incubated with rotation for 2 h at 41C. After adding protein A-agarose bead suspension (ImmunoPure immobilized protein A; Pierce), the mixture was further incubated with rotation for 2 h at 41C. After three washes with the lysis buffer, the beads were resuspended in Laemmli sample buffer and boiled for 2 min. After centrifugation at 10 000 Â g for 30 s at 41C, the supernatant was subjected to SDS-PAGE and subsequent Western blotting.
Western blot
The proteins were separated using 10% SDS-PAGE and transferred to a Hybond P membrane (Amersham Biosciences). The membrane was probed with anti-HDAC2 antibody or anti-HA antibody. The donkey anti-rabbit IgG horseradish peroxidase-conjugated antibody (Amersham Biosciences) was used as the secondary antibody. The proteins were detected using ECL-Plus Western blotting detection system (Amersham Biosciences) and visualized with LAS-1000 Luminoimage analyzer (Fuji film).
Reverse transcriptase-polymerase chain reaction hTERT and TEP1 expression were analysed by reverse transcriptase (RT)-PCR as previously described (Katakura et al., 1999) . RNA was isolated with GenElute Mammalian Total RNA Miniprep kit (Sigma), and cDNA was prepared using M-MLV RT RNase H À (Promega) according to the manufacturer's protocol. The PCR products were subjected to electrophoresis on an 8% polyacrylamide gel.
Quantitative real-time PCR RNA was prepared using the RNeasy RNA isolation kit (Qiagen, Hilden, Germany) and digested with DNase on-column using RNase-free DNase (Qiagen). cDNA was prepared as described. Quantitative PCR was performed using SYBR Premix Ex Taq (TaKaRa, Shiga, Japan) and Thermal Cycler Dice Real Time System TP-800 instrument (TaKaRa). PCR amplification began with a 10-s denaturation step at 951C and then 40 cycles of denaturation at 951C for 5 s, annealing at 551C for 20 s, and extension at 721C for 20 s. The samples were analysed in triplicate, and the TAK1 and hTERT levels were normalized to the corresponding GAPDH levels. The PCR primer sequences used were as follows: TAK1 top primer AGCAAGTTCCTGC CACAAATGATAC and bottom primer GCGGCGATCCTA GCTTCTATTTC; hTERT top primer CGTACAGGTTTCAC GCATGTG and bottom primer ATGACGCGCAGGAAAA ATG; human GAPDH top primer GCACCGTCAAGGCTGA GAAC and bottom primer ATGGTGGTGAAGACGCCAGT.
Small interfering RNA treatment Cells were transfected with 5 nM small interfering RNA (siRNA) by using HiPerFect transfection reagent (Qiagen). Validated siRNA directed against TAK1 (Hs MAP3K7 10 HP) was purchased from Qiagen. After the culture medium was replaced with fresh medium the following day, the cells were cultured for an additional 4 days. Where indicated, these cells were further transduced with recombinant adenovirus and cultured for a further 3 days.
Senescence-associated b-galactosidase (SA-b-Gal) assay SA-b-Gal assay was performed according to the method described by Dimri et al. (1995; Katakura et al., 1999) . Staining was performed at 371C for 12 h.
